Hanna Rahbek Mortensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hanna Rahbek Mortensen has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Britta Weber
Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
3 shared publications - Lone Hoffmann
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark
3 shared publications - Ditte Sloth Møller
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health Science, Aarhus University, Aarhus, Denmark
2 shared publications - Kenneth Jensen
Danish Centre for Particle Therapy, Aarhus University Hospital, Denmark
2 shared publications Maria Fuglsang Jensen
Danish Centre for Particle Therapy, Aarhus University Hospital, Denmark
2 shared publications- Tine Schytte
Department of Oncology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark
2 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Elsevier in Physica Medica
- Vol. 147, 105830
Respiratory gated proton therapy for liver cancer: Setup and gating validation based on fiducial marker motion extracted from 2D kV projection images acquired during cone-beam CT
- 3 June 2026
- Published by Elsevier in Physica Medica
- Vol. 147, 105830
Open AccessRespiratory gated proton therapy for liver cancer: Setup and gating validation based on fiducial marker motion extracted from 2D kV projection images acquired during cone-beam CT
- Open Access
- 20 November 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 214, 111293
Development of a treatment planning protocol for the multi-centre reirradiation CURE Lung trial
- 20 November 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 214, 111293
Open AccessDevelopment of a treatment planning protocol for the multi-centre reirradiation CURE Lung trial
- Open Access
- 15 October 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1412-1419
Real-world outcomes after concurrent chemo-radiotherapy in patients with locally advanced esophageal and gastroesophageal junction cancer
Background and purpose: Standard treatment for esophageal (EC) and gastroesophageal junction (GEJ) cancer includes neoadjuvant chemo-radiotherapy (nCRT), followed by surgery or definitive chemo-radiotherapy (dCRT) for inoperable patients. This study assessed real-world survival and morbidity in EC patients treated with radiotherapy (RT). Patient/material and methods: In this retrospective study, 417 patients with EC or GEJ cancer received nCRT or dCRT between 2012 and 2021 at a single center. We evaluated overall survival (OS), loco-regional control, progression-free survival, failure patterns, and toxicity. Data were sourced from clinical and treatment records. Patients were treated following national guidelines and received intensity-modulated radiotherapy and daily cone-beam Computed Tomography (CT) for setup. Radiotherapy doses were 41.4–66 Gy in 23–33 fractions. Results: Of the patients, 250 received nCRT, and 167 received dCRT. Most (86%) had T3-T4 tumors, and 65% had node-positive disease. Histologies were adenocarcinoma (50%) and squamous cell carcinoma (45%). A total of 88% completed RT, and 92.4% of nCRT patients proceeded to surgery. Median OS was 31 months for nCRT and 24 months for dCRT; 3-year OS was 46% and 38%, respectively. Disease recurrence occurred in 46% with a median interval of 20 months. Multivariable analysis identified OS-associated factors for both nCRT and dCRT. Acute toxicity was common but generally mild; late side effects were not systematically recorded. Interpretation: In clinical practice, OS after nCRT or dCRT was as expected. Most patients undergoing nCRT proceeded to surgery. Toxicity was frequent but manageable.
- 15 October 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1412-1419
Open AccessReal-world outcomes after concurrent chemo-radiotherapy in patients with locally advanced esophageal and gastroesophageal junction cancer
Background and purpose: Standard treatment for esophageal (EC) and gastroesophageal junction (GEJ) cancer includes neoadjuvant chemo-radiotherapy (nCRT), followed by surgery or definitive chemo-radiotherapy (dCRT) for inoperable patients. This study assessed real-world survival and morbidity in EC patients treated with radiotherapy (RT). Patient/material and methods: In this retrospective study, 417 patients with EC or GEJ cancer received nCRT or dCRT between 2012 and 2021 at a single center. We evaluated overall survival (OS), loco-regional control, progression-free survival, failure patterns, and toxicity. Data were sourced from clinical and treatment records. Patients were treated following national guidelines and received intensity-modulated radiotherapy and daily cone-beam Computed Tomography (CT) for setup. Radiotherapy doses were 41.4–66 Gy in 23–33 fractions. Results: Of the patients, 250 received nCRT, and 167 received dCRT. Most (86%) had T3-T4 tumors, and 65% had node-positive disease. Histologies were adenocarcinoma (50%) and squamous cell carcinoma (45%). A total of 88% completed RT, and 92.4% of nCRT patients proceeded to surgery. Median OS was 31 months for nCRT and 24 months for dCRT; 3-year OS was 46% and 38%, respectively. Disease recurrence occurred in 46% with a median interval of 20 months. Multivariable analysis identified OS-associated factors for both nCRT and dCRT. Acute toxicity was common but generally mild; late side effects were not systematically recorded. Interpretation: In clinical practice, OS after nCRT or dCRT was as expected. Most patients undergoing nCRT proceeded to surgery. Toxicity was frequent but manageable.
- Open Access
- 5 August 2025
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 35, 100820
An interactive deep-learning workflow for head and neck gross tumour volume segmentation
- 5 August 2025
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 35, 100820
Open AccessAn interactive deep-learning workflow for head and neck gross tumour volume segmentation
- Open Access
- 22 May 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 209, 110950
Recommendations for radiotherapy quality assurance in clinical trials
- 22 May 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 209, 110950
Open AccessRecommendations for radiotherapy quality assurance in clinical trials
- Open Access
- 30 September 2024
- Published by Korean Liver Cancer Association in Journal of Liver Cancer
- Vol. 24 (2) , 286-302
Recent update of proton beam therapy for hepatocellular carcinoma: a systematic review and meta-analysis
Backgrounds/Aims: Although access to proton beam therapy (PBT) is limited worldwide, its use for the treatment of hepatocellular carcinoma (HCC) is gradually increasing with the expansion of new facilities. Therefore, we conducted a systematic review and metaanalysis to investigate the updated evidence of PBT for HCC.Methods: The MEDLINE, EMBASE, Cochrane Library, and Web of Science databases were systematically searched for studies that enrolled patients with liver-confined HCC that were treated with PBT for a cure up to February 2024.Results: A total of 1,858 HCC patients receiving PBT from 22 studies between 2004 and 2023 were selected for this meta-analysis. The median proportion of Child-Pugh class A was 86% (range, 41-100), and the median tumor size was 3.6 cm (range, 1.2-9.0). The median total dose ranged from 55 GyE to 76 GyE (median, 69). The pooled rates of 3- and 5-year local progression-free survival after PBT were 88% (95% confidence interval [CI], 85-91) and 86% (95% CI, 82-90), respectively. The pooled 3- and 5-year overall rates were 60% (95% CI, 54-66) and 46% (95% CI, 38-54), respectively. The pooled rates of grade 3 hepatic toxicity, classic radiationinduced liver disease (RILD), and non-classic RILD were 1%, 2%, and 1%, respectively.Conclusions: The current study supports PBT for HCC and demonstrates favorable long-term survival and low hepatic toxicities compared with other published studies on other radiotherapy modalities. However, further studies are needed to identify the subgroups that will benefit from PBT.
- 30 September 2024
- Published by Korean Liver Cancer Association in Journal of Liver Cancer
- Vol. 24 (2) , 286-302
Open AccessRecent update of proton beam therapy for hepatocellular carcinoma: a systematic review and meta-analysis
Backgrounds/Aims: Although access to proton beam therapy (PBT) is limited worldwide, its use for the treatment of hepatocellular carcinoma (HCC) is gradually increasing with the expansion of new facilities. Therefore, we conducted a systematic review and metaanalysis to investigate the updated evidence of PBT for HCC.Methods: The MEDLINE, EMBASE, Cochrane Library, and Web of Science databases were systematically searched for studies that enrolled patients with liver-confined HCC that were treated with PBT for a cure up to February 2024.Results: A total of 1,858 HCC patients receiving PBT from 22 studies between 2004 and 2023 were selected for this meta-analysis. The median proportion of Child-Pugh class A was 86% (range, 41-100), and the median tumor size was 3.6 cm (range, 1.2-9.0). The median total dose ranged from 55 GyE to 76 GyE (median, 69). The pooled rates of 3- and 5-year local progression-free survival after PBT were 88% (95% confidence interval [CI], 85-91) and 86% (95% CI, 82-90), respectively. The pooled 3- and 5-year overall rates were 60% (95% CI, 54-66) and 46% (95% CI, 38-54), respectively. The pooled rates of grade 3 hepatic toxicity, classic radiationinduced liver disease (RILD), and non-classic RILD were 1%, 2%, and 1%, respectively.Conclusions: The current study supports PBT for HCC and demonstrates favorable long-term survival and low hepatic toxicities compared with other published studies on other radiotherapy modalities. However, further studies are needed to identify the subgroups that will benefit from PBT.
- 5 November 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 190, 109980
Proton versus photon therapy for esophageal cancer – A trimodality strategy (PROTECT) NCT050555648
- 5 November 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 190, 109980
Proton versus photon therapy for esophageal cancer – A trimodality strategy (PROTECT) NCT050555648
- Open Access
- 7 December 2022
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 58 (6) , 583-588
Defining dysphagia – a modified multi-professional Danish Delphi study
- 7 December 2022
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 58 (6) , 583-588
Open AccessDefining dysphagia – a modified multi-professional Danish Delphi study